Clinical trials: Oral Phase
Healthy
CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)
The purpose of this study is to evaluate the dose-related safety, tolerability, pharmacokinetics (PK) and pharmacological effects (PD) of CORT125134 and its active metabolite CORT125201 after single and multiple ascending oral…
- Trial name
- NCT03508635
- Testing
- CORT125134, Mifepristone, Prednisone
- Where
- United Kingdom
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Parkinson Disease, Healthy Participants
A Study of TAK-071 in People With Parkinson Disease
It is hoped that TAK-071 will help people with Parkinson's disease to walk with better balance. The main aim of the study is to check if there is a difference in how participants walk after treatment with TAK-071.
- Trial name
- NCT04334317
- Testing
- TAK-071
- Where
- 21 sites in United States
- Volunteers
- 64 people
- Sponsor
- Takeda
Elderly Subjects With Underlying Diseases
A Study in Elderly Chinese Subjects With Underlying Diseases
Evaluate the safety and tolerability of oral JT001 tablets in elderly subjects with underlying diseases. Evaluate the pharmacokinetic characteristics of JT001 tablets orally administered to elderly subjects with underlying…
- Trial name
- NCT06093308
- Testing
- Deuremidevir Hydrobromide Tablets
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.
Respiratory Syncytial Viruses
A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus
The purpose of this study is to determine in hospitalized infants and children who are infected with respiratory syncytial virus (RSV) the dose-response relationship of multiple regimens of lumicitabine on antiviral activity…
- Trial name
- NCT03333317
- Testing
- Lumicitabine
- Where
- 29 sites in United States, Belgium and 4 more
- Volunteers
- 7 people
- Sponsor
- Janssen Research & Development, LLC
Atopic Dermatitis
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
This phase 2b study is designed to evaluate the safety and efficacy of KT-621 in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema.
- Trial name
- BROADEN2 (NCT07217015)
- Testing
- KT-621
- Where
- 61 sites in United States, Australia and 6 more
- Volunteers
- 200 people
- Sponsor
- Kymera Therapeutics, Inc.
Niemann-Pick Type C Disease
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease
- Trial name
- NCT07082725
- Testing
- Nizubaglustat
- Where
- 34 sites in United States, Argentina and 13 more
- Volunteers
- 72 people
- Sponsor
- Azafaros B.V.
Healthy
Single Ascending Oral Dose Study to Investigate the Effects of OCT461201 in Healthy Volunteers
A study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of OCT461201. The study included a screening period, a single dose of study treatment or placebo and a follow up period.
- Trial name
- NCT06398925
- Testing
- OCT461201 50 mg, OCT461201 100 mg, OCT461201 150 mg
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Oxford Cannabinoid Technologies Holdings PLC
Diabetes Mellitus, Type 2
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.
- Trial name
- NCT01131676
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 615 sites in United States, Argentina and 40 more
- Volunteers
- 7,064 people
- Sponsor
- Boehringer Ingelheim
Eosinophilic Esophagitis
Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation
This is a Phase 1, investigator- and participant-blinded, placebo-controlled, randomized, crossover study to compare bioavailability of AQ280 following single oral doses of a capsule formulation versus a tablet for oral…
- Trial name
- NCT07093008
- Testing
- AQ280 Capsule, AQ280 Tablet for Oral Suspension
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- AQILION AB
Non-Small Cell Lung Cancer, Melanoma
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.
- Trial name
- NCT02974725
- Testing
- LXH254, LTT462, Trametinib
- Where
- 32 sites in United States, Australia and 9 more
- Volunteers
- 241 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Constipation
Trial of Linaclotide in Patients With Chronic Constipation
The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (CC).
- Trial name
- NCT00730015
- Testing
- Linaclotide
- Where
- 105 sites in United States
- Volunteers
- 643 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Head and Neck Neoplasms, Mucositis
Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer
Oral Mucositis (OM) is a painful and debilitating side effect of many of the drug/radiation regimens used to treat cancer. This study examines the investigational drug brilacidin and its possible application in prevention of oral…
- Trial name
- Brilacidin (NCT02324335)
- Testing
- Brilacidin
- Where
- 16 sites in United States
- Volunteers
- 61 people
- Sponsor
- Innovation Pharmaceuticals, Inc.
Hepatic Impairment, Advanced Malignant Solid Tumor
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
This main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the study drug tazemetostat. The pharmacokinetics of the study drug in participants with advanced solid tumors and moderate or severe…
- Trial name
- NCT04241835
- Testing
- Tazemetostat
- Where
- 14 sites in United States, Belgium and 3 more
- Volunteers
- 18 people
- Sponsor
- Epizyme, Inc.
Gout
Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.
The purpose of this study is to compare febuxostat, allopurinol and placebo, once daily (QD), in subjects with gout.
- Trial name
- APEX (NCT00174915)
- Testing
- Febuxostat, Allopurinol
- Volunteers
- 1,072 people
- Sponsor
- Takeda
Colonic Diseases
A Clinical Phase I Study on GIC-1001 in Healthy Volunteers
The objectives of this single center, randomized, double-blinded, placebo-controlled Phase I clinical study are to evaluate the safety and tolerability of five (5) single and four (4) multiple increasing oral doses of GIC-1001…
- Trial name
- NCT01738425
- Testing
- GIC-1001; 125 mg oral tablets
- Where
- Canada
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- gicare Pharma Inc.
Alzheimer Disease
BnH-015B Clinical Trial in Moderate Alzheimer's Disease
BnH-015B is a small molecule compound that targets the GluN2B binding site on NMDA receptors and positively modulates. BnH-015B has shown, through nonclinical trials, to improve symptoms of cognitive decline by regulating the…
- Trial name
- NCT06535308
- Testing
- BnH-015B 5 mg, BnH-015B 10 mg, BnH-015B 20 mg
- Where
- South Korea
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- BnH Research
Pain
Relative Bioavailability and Food Effect Study
Initial studies have used a powder in capsule formulation of PH797804. In future studies an immediate release tablet will be used.
- Trial name
- NCT00827515
- Testing
- PH797804
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus
Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252
The purpose of this study is to evaluate the safety, tolerability, and PK of single oral doses of JTT-252 and the effect of food on the PK of JTT-252 in healthy subjects, and to evaluate the safety, tolerability, PK and PD of…
- Trial name
- NCT02120976
- Testing
- JTT-252
- Where
- 2 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Shionogi Inc.
Healthy Volunteers
Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension
This study will evaluate the amount of drug that reaches the circulation when a subject takes the test (liquid) formulation compared to the reference (capsule) formulation.
- Trial name
- NCT02521714
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Celgene
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH).
- Trial name
- ROCSTAR (NCT07175038)
- Testing
- ROC-101
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AllRock Bio, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.